Hormonal Effects on Upper-Airway Function in Women

Abstract

Upper-airway function in women is intricately modulated by hormonal fluctuations across the lifespan, with significant implications for respiratory health and sleep-related breathing disorders. This review synthesizes current scientific evidence on the interplay between sex hormones primarily estrogen and progesterone and upper-airway physiology, emphasizing mechanisms of action, clinical manifestations, and guideline-based management strategies. Key areas discussed include the epidemiology of upper-airway dysfunction in women, pathophysiological mechanisms underlying hormone-mediated changes, risk factors, diagnostic approaches, therapeutic options, and recent advances in the field. The article provides clinicians with practical, evidence-based insights relevant for optimizing care in female patients affected by upper-airway disorders.

Introduction

The upper airway serves as a critical conduit for airflow and plays a pivotal role in maintaining adequate ventilation, especially during sleep. In women, upper-airway function is subject to unique influences from endogenous and exogenous hormonal changes that occur throughout life from puberty and menstrual cycling through pregnancy, menopause, and hormone replacement therapy. Understanding the hormonal modulation of upper-airway patency, muscle tone, and respiratory control is essential for clinicians managing conditions such as obstructive sleep apnea (OSA), snoring, and upper-airway resistance syndrome (UARS). This review explores the current scientific landscape surrounding hormonal effects on upper-airway function in women and provides evidence-based recommendations for clinical practice.

Epidemiology / Disease Burden

Respiratory sleep disorders, particularly OSA, have historically been considered more prevalent in men; however, epidemiological data reveal a substantial disease burden among women, particularly post-menopause. The prevalence of OSA in premenopausal women is estimated at 2-4%, rising to 10-20% following menopause, approaching rates seen in men. Additionally, women are more likely to present with atypical symptoms such as insomnia, fatigue, and mood disturbances, complicating diagnosis and contributing to underrecognition. Hormonal transitions menstrual cycle fluctuations, pregnancy, and menopause are associated with dynamic changes in upper-airway collapsibility, highlighting the need for heightened clinical vigilance and tailored management in female populations.

Pathophysiology

Sex hormones exert multifaceted effects on upper-airway structure and neuromuscular function. Estrogen enhances upper-airway muscle tone by upregulating neurotransmitter receptors and promoting synaptic transmission in hypoglossal motor neurons, which innervate the genioglossus and other pharyngeal dilator muscles. Progesterone augments central respiratory drive and increases ventilatory responsiveness to hypercapnia and hypoxia, reducing the propensity for airway collapse. During the luteal phase of the menstrual cycle, elevated progesterone levels are associated with improved upper-airway stability, whereas the follicular phase may predispose to increased collapsibility. Pregnancy is characterized by rising estrogen and progesterone levels, resulting in mucosal edema and increased airway resistance, but also a protective increase in ventilatory drive. Conversely, menopause is marked by declining estrogen and progesterone, leading to reduced neuromuscular compensation and heightened risk for OSA.

Risk Factors

Risk factors for upper-airway dysfunction in women include hormonal transitions (puberty, menstrual cycle, pregnancy, menopause), obesity, craniofacial anatomy, and comorbid conditions such as hypothyroidism and polycystic ovary syndrome (PCOS). Exogenous factors, including oral contraceptives and hormone replacement therapy, may further modify risk profiles. Genetic predisposition, age, and ethnicity also contribute to interindividual variability in upper-airway responses to hormonal changes. Recognizing these risk factors is critical for early identification and intervention in susceptible women.

Clinical Features

Women with upper-airway dysfunction may present with classic symptoms such as snoring and witnessed apneas, but more commonly exhibit non-specific manifestations including excessive daytime sleepiness, insomnia, morning headaches, depression, and cognitive impairment. During pregnancy, symptoms may be aggravated by weight gain and mucosal congestion. Postmenopausal women are at increased risk for OSA, often underdiagnosed due to atypical presentations. Clinical suspicion should be heightened in women reporting new-onset sleep disturbances coinciding with hormonal transitions.

Diagnosis

Diagnostic evaluation includes a thorough clinical assessment, targeted history focusing on hormonal milestones, and objective sleep studies such as polysomnography. Home sleep apnea testing may be considered in selected patients, though in-lab studies are preferred for comprehensive assessment. Consideration of hormonal status, menstrual cycle phase, and use of exogenous hormones is essential for accurate interpretation of findings. Additional investigations may include upper-airway imaging and assessment of comorbidities impacting airway function.

Treatment & Management

Management strategies are tailored to the underlying hormonal milieu and severity of upper-airway dysfunction. First-line therapy for OSA remains positive airway pressure (PAP) therapy, with adjunctive measures including weight management, positional therapy, and oral appliance therapy. In perimenopausal and postmenopausal women, hormone replacement therapy (HRT) may be considered in select cases, although current evidence does not support routine use solely for OSA management. Pregnancy-specific considerations include positional therapy and close monitoring, with avoidance of sedative medications. Multidisciplinary collaboration is recommended for women with complex hormonal and respiratory presentations.

Recent Advances / Emerging Therapies

Recent research has elucidated novel mechanisms by which estrogen and progesterone modulate upper-airway patency, including effects on synaptic plasticity and inflammatory pathways. Advances in pharmacological interventions targeting serotonergic and noradrenergic pathways hold promise for enhancing upper-airway tone. Personalized medicine approaches, integrating genetic, hormonal, and phenotypic data, are emerging to optimize treatment selection. Ongoing clinical trials are evaluating the role of selective estrogen receptor modulators and novel neuromodulatory agents in women with OSA and related disorders.

Guideline Recommendations

Professional society guidelines emphasize the importance of gender- and hormone-specific considerations in the evaluation and management of upper-airway dysfunction. The American Academy of Sleep Medicine recommends heightened clinical awareness in women, particularly during hormonal transitions. Routine screening for sleep-disordered breathing is advocated in pregnant and postmenopausal women with suggestive symptoms. Individualized care plans, integrating hormonal, anatomical, and lifestyle factors, are endorsed to achieve optimal outcomes.

Conclusion

Hormonal influences on upper-airway function in women represent a complex but clinically significant domain with direct implications for the diagnosis and management of respiratory sleep disorders. A nuanced understanding of the interplay between sex hormones and upper-airway physiology enables clinicians to provide tailored, evidence-based care for female patients across the lifespan. Ongoing research and emerging therapies are poised to further refine management strategies, with the ultimate goal of improving respiratory health and quality of life in women.